DUBLIN--(BUSINESS WIRE)--The "Crohn's Disease and Ulcerative Colitis Pricing, Reimbursement, and Access" report has been added to ResearchAndMarkets.com's offering.
Payers view spending on inflammatory bowel disease (IBD) drugs as significant, as there is a large patient base requiring expensive biologic therapies. The market has been long dominated by the TNF-alpha inhibitors Humira and Remicade, but more recent biologic launches such as Entyvio and Stelara have focused on novel mechanisms of action. Additionally, another alpha integrin, etrolizumab, is a further biologic of interest to clinicians.
The IBD pipeline is also expecting the launches of novel oral agents such as JAK inhibitors Xeljanz and filgotinib, as well as the S1P receptor antagonist ozanimod. Payers fully expect that these pipeline agents will continue to fuel the growth of the IBD market, and that the launches of TNF-alpha inhibitor biosimilars will not do much to temper growth. Consequently, payers have been restricting the prescribing of the non-TNF-alpha inhibitors to later lines of therapy - and after the TNF-alpha inhibitors whenever possible - to ensure biosimilar savings are realized.
European payers are enacting national and regional restrictions: using start-and-stop criteria, delineating therapeutic lines, and requiring discounts in exchange for access to earlier lines of treatment. US payers mandate prior authorization, with most payers requiring failures with TNF-alpha inhibitors prior to accessing Entyvio or Stelara.
Key Topics Covered:
- Executive Summary
- Regulatory Labels
- Global Access Levers And Barriers
- Access To Recently Launched And Pipeline Products
- Value And Evidence
- US Pricing
- US Reimbursement
- Biosimilar Tnf-Alpha Inhibitors In The Five Major EU Markets
- Pricing In The Five Major EU Markets
For more information about this report visit https://www.researchandmarkets.com/research/tm77tn/crohns_disease?w=4